Early Warning System

IFC-39739

Farmoquimica

Early Warning System
Farmoquimica

IFC-39739

Quick Facts

Countries	Brazil
Financial Institutions	International Finance Corporation (IFC)
Status	Proposed
Bank Risk Rating	B
Borrower	DIVCOM PHARMA
Sectors	Education and Health
Investment Type(s)	Loan
Investment Amount (USD)	$ 116.00 million
Loan Amount (USD)	$ 116.00 million
Project Cost (USD)	$ 116.00 million

Project Description

Farmoquimica or “the company” (www.fqm.com.br), is a Brazilian pharmaceutical company selling branded prescription drugs; with a product line that includes more than 50 branded drugs among 9 specialties. The company is fully owned by Laboratorios Roemmers S.A., Argentina's largest pharmaceutical company and #5 player in LAC.
The proposed IFC investment includes a loan for a total of up to USD 116 million; including US$31 million from its own account and the balance from syndication. The proposed investment will be used to support the business combination between FQM and Divcom and finance the acquisition of brands commercialized by Divcom. Divcom Pharma (www1.divcom.com.br/divc/home/index.html) is a medium-sized manufacturer and distributor of Over the Counter (OTC) medicines in Brazil's Northeast (the “project”).

Investment Description

- International Finance Corporation (IFC)

Contact Information

ACCOUNTABILITY MECHANISM OF IFC

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org. You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org/